AVOS Life Sciences

Table of Contents - Depression

Disease Etiology 6
Epidemiology & Patient Population Estimates 7
Theoretical Patient Population 7
Addressable Patient Population 7
Major Depressive Disorder 7
Somatic Presenting Patients 8
Anxiety Disorders 8
Dysthymic Disorder 8
Depression Rating Scales 8
Hamilton Depression Rating Scale 8
Hamilton Anxiety Rating Scale 9
Clinical Global Impression 9
Treated Patient Population 9
Treated with Antidepressants and Patient
Compliance 9
Depression and Dysthymia 9
Anxiety 9
Bipolar Disorder 9
U.S. Depression Patient Population Model 10
Disease & Market Definitions 11
Forecasting Methodology 11
Market Revenue Forecasts 12
U.S. Depression Market Model, 2004-2013 14
AVOS Physician Panel Results 16
Physician Treatment Patterns 16
Differences Between Psychiatrists and PCPs 16
Patient Compliance 17
Reasons for Non-Compliance 18
Physician Product Selection Criteria 19
Patient Response 19
Side Effect Profile 19
Availability of Samples 19
Patient Preference/Family History 19
Past Experience 19
Approaches to Differentiation 20
Treatment of Anxiety 20
Benign/Niche Side Effect Profiles 20
Refractory/Remission Treatment 20
Treatment of Somatic Symptoms 20
Brand vs. Generic Quality 20
Physician Product Ratings 21
Market Overview 24
Leading Products 25
Current Market Environment 25
Future Market Environment 26
New Mechanisms of Action 26
Increased Use of SNRIs 26
Competitive Promotion 26
Increased Use in Elderly Populations 26
Genetic Testing Far Off 26
Product Profiles 27
Effexor Franchise 27
U.S. Perspective 27
Worldwide Perspective 28
AVOS Physician Panel Discussions 28
Franchise History 29
Lexapro 30
U.S. Perspective 30
Worldwide Perspective 31
AVOS Physician Panel Discussions 31
Cymbalta 32
U.S. Perspective 32
Worldwide Perspective 33
AVOS Physician Panel Discussions 33
Pain Treatment Drives Growth 34
Neuropathic Pain 34
Treatment of Neuropathic Pain 34
Wellbutrin Franchise 35
U.S. Perspective 35
Worldwide Perspective 36
AVOS Physician Panel Discussions 36
Franchise History 37
Paxil Franchise 38
U.S. Perspective 38
Worldwide Perspective 39
AVOS Physician Panel Discussions 39
Zoloft 40
U.S. Perspective 40
Worldwide Perspective 40
AVOS Physician Panel Discussions 41
Prozac Franchise 42
U.S. Perspective 42
Worldwide Perspective 42
AVOS Physician Panel Discussions 42
Franchise History 43
Celexa 44
U.S. Perspective 44
Worldwide Perspective 44
AVOS Physician Panel Discussions 44
Gepirone-ER 45
U.S. Perspective 45
Worldwide Perspective 46
AVOS Physician Panel Discussions 46
Saredutant 47
U.S. Perspective 47
Worldwide Perspective 48
AVOS Physician Panel Discussions 48
Amibegron 49
U.S. Perspective 49
Worldwide Perspective 50
AVOS Physician Panel Discussions 50
Agomelatine 51
U.S. Perspective 51
Worldwide Perspective 52
AVOS Physician Panel Discussions 52
Pristiq 53
U.S. Perspective 53
Worldwide Perspective 54
AVOS Physician Panel Discussions 54
Clinical Trials 54
Wyeth's Shifting Strategy 54
Vilazodone 56
U.S. Perspective 56
Worldwide Perspective 57
Product License History 57
AVOS Physician Panel Discussions 57
Drugs in Development 58
R&D Overview 58
Assessment of R&D Success Rates 59
Products in the Pipeline 61
Pre-Registration (five agents) 61
Phase III (five agents) 61
Phase II (20 agents) 61
Cover

Production date: September 2007

Order

Print Copy - $5,000

Single Site license PDF - $7,000

Global License PDF - $9,995

Contact Information:

If you wish to see sample pages or to learn more about AVOS Therapeutic Market Reports, contact Mike Goodman
919-475-9695
reports@avoslifesciences.com